• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:郑云茹,陈红,魏欣琪,褚克丹,徐伟,刘剑.一氧化氮供体和阿霉素的共递送系统用于逆转肿瘤低氧耐药研究[J].药学研究,2022,41(1):1-8,30[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2466次   下载 3436次 本文二维码信息
码上扫一扫!
一氧化氮供体和阿霉素的共递送系统用于逆转肿瘤低氧耐药研究
郑云茹,陈红,魏欣琪,褚克丹,徐伟,刘剑
字体:加大+|默认|缩小-
(福建中医药大学药学院,福建 福州 350122)
摘要:
目的 构建一种一氧化氮供体和阿霉素的共递送系统,以逆转肿瘤低氧耐药。方法 利用酰胺反应合成一氧化氮供体单硝酸异山梨酯(IM)修饰的透明质酸(HA-IM),再通过硫化学作用将其嫁接于二硫化钼(MoS2)纳米片,制备出载体二硫化钼-单硝酸异山梨酯修饰的透明质酸(MoS2-HA-IM),考察此载体的理化特性。通过疏水作用装载抗癌药阿霉素(DOX),构建一氧化氮供体和抗癌药物的共递送系统,并在细胞水平上考察此系统的抗肿瘤效果。结果 二硫化钼-单硝酸异山梨酯修饰的透明质酸-阿霉素(MoS2-HA-IM-DOX)可通过透明质酸受体介导的内吞作用有效地将装载的单硝酸异山梨酯和阿霉素输送到肿瘤细胞内,且在肿瘤弱酸性内环境和近红外光照射的双重刺激下迅速将药物释放出来,提高胞内游离药物的浓度。同时,装载的单硝酸异山梨酯能够逆转肿瘤细胞的低氧耐受性,进一步增强MoS2-HA-IM-DOX的化疗效果,再联合基于MoS2材料产生的光热,共使肿瘤细胞的生长抑制率高达93.6%,明显高于其他组。结论 MoS2-HA-IM-DOX能够靶向输送一氧化氮供体和抗癌药物至肿瘤细胞内,双重响应控制药物释放,逆转肿瘤低氧耐药,最大限度地提高化疗效果,结合光热治疗,显示出优异的抗肿瘤效果。
关键词:  二硫化钼  透明质酸  肿瘤低氧耐药  近红外光  化学/光热协同治疗
DOI:10.13506/j.cnki.jpr.2022.01.001
基金项目:国家青年自然科学基金(No.8210142844);福建省科技厅课题基金(No.2021J01131548);福建中药大学校管课题(No.X2020009-重点)
出版日期:2022-01-25
Co-delivery system of nitric oxide donor and DOX for reversing hypoxia-induced drug resistance in tumor
ZHENG Yunru,CHEN Hong,WEI Xinqi,CHU Kedan,XU Wei,LIU Jian
(College of Pharmacy,Fujian University of Traditional Chinese Medicine,Fuzhou 350122,China)
Abstract:
Objective Constructing a co-delivery system of nitric oxide donor and DOX is used to reverse the hypoxia-induced drug resistance in tumor.Methods Hyaluronic acid (HA) modified with nitric oxide donor isosorbide mononitrate (IM) was synthesized by the amidation reaction, and then grafted onto molybdenum disulfide (MoS2) nanosheets by sulfur chemistry to prepare the carrier MoS2-HA-IM. Meanwhile, the physicochemical properties of MoS2-HA-IM nanosheets were investigated. The anticancer drug doxorubicin (DOX) was loaded onto the carrier by hydrophobic interaction, constructing a co-delivery system of a nitric oxide donor and DOX, and the antitumor effect of this system was investigated at the cellular level. Results MoS2-HA-IM-DOX could effectively deliver the loaded IM and DOX into tumor cells via HA receptor-mediated endocytosis, and the drug was rapidly released under the dual stimulation of tumor acidic microenvironment and near-infrared light irradiation, obviously increasing the intracellular free drug concentration. Meanwhile, the loaded IM was able to reverse the hypoxic tolerance of tumor cells, further enhancing the chemotherapeutic effect of MoS2-HA-IM-DOX. More importantly, the growth inhibition rate of tumor cells was up to 93.6%, significantly higher than other groups, mainly due to the combination of the chemotherapy and the MoS2-based photothermal effect. Conclusion MoS2-HA-IM-DOX can achieve the targeted delivery of nitric oxide donors and anticancer drugs into tumor cells, the control release of drugs under a dual-response stimulus, the reversal of hypoxia-induced drug resistance in tumors, maximizing the chemotherapy effect, and exhibit excellent antitumor effects in combination with photothermal therapy.
Key words:  Molybdenum disulfide  Hyaluronic acid  Tumor hypoxia resistance  Near-infrared light  Chemo/photothermal synergistic therapy
今日访问量:2495    总访问量:55338938
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司